Precision BioSciences Announces First Patient Dosed in PBGENE‑DMD Trial

What Happened

• Precision BioSciences, Inc. (DTIL) announced via an 8‑K filed August 24, 2026 that the first patient has been dosed in its Phase 1/2 FUNCTION‑DMD clinical trial of PBGENE‑DMD, a candidate for the treatment of Duchenne muscular dystrophy (DMD). The dosing occurred at Arkansas Children’s Hospital. The company furnished a press release as Exhibit 99.1 to the Form 8‑K.

Key Details

• Date filed: August 24, 2026 (Current Report on Form 8‑K; Regulation FD disclosure).
• Program: PBGENE‑DMD for Duchenne muscular dystrophy, Phase 1/2 trial named FUNCTION‑DMD.
• Clinical site: First patient dosed at Arkansas Children’s Hospital.
• Disclosure: Press release attached as Exhibit 99.1; Form 8‑K signed by CFO Naresh Tanna.

Why It Matters

• First‑patient dosing is a concrete clinical milestone that advances the PBGENE‑DMD development program from preclinical/early steps into active human testing. For investors, this is an operational progress marker that can affect program timelines and future data‑driven value inflection points (e.g., safety and efficacy readouts).
• The 8‑K and press release are formal, public disclosures under Regulation FD, ensuring broad market access to the update.